^
    4d
    Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma (clinicaltrials.gov)
    P1, N=50, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Jul 2026 --> Jul 2027
    Trial completion date
    |
    BRAF V600
    |
    Opdivo (nivolumab) • Mektovi (binimetinib) • Braftovi (encorafenib)
    4d
    STARBOARD: A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma (clinicaltrials.gov)
    P3, N=257, Active, not recruiting, Pfizer | Trial completion date: Mar 2026 --> Aug 2026
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • BRAF V600K
    |
    Keytruda (pembrolizumab) • Mektovi (binimetinib) • Braftovi (encorafenib)
    7d
    Phase I Trial of Binimetinib Plus Hydroxychloroquine in Patients with Previously Treated Metastatic Pancreatic Cancer. (PubMed, Oncologist)
    The combination of BINI + HCQ demonstrated a challenging toxicity profile and limited clinical activity in patients with chemorefractory metastatic PDAC.
    P1 data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • RAS mutation
    |
    Mektovi (binimetinib) • hydroxychloroquine
    7d
    Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF‑mutated metastatic colorectal cancer: The BEETS (JACCRO CC‑18) study. (PubMed, Oncologist)
    In real-world clinical practice, triplet and doublet therapies showed comparable survival outcomes, consistent with the BEACON trial. Triplet therapy may provide potential clinical benefit in patients with poor PFs.
    Journal • Real-world evidence
    |
    BRAF (B-raf proto-oncogene) • CRP (C-reactive protein)
    |
    BRAF V600E • BRAF mutation • BRAF V600
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • Braftovi (encorafenib)
    19d
    Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancer. (PubMed, Lung Cancer)
    Regimens co-targeting the MAPK pathway and ALK or ROS1 had limited efficacy in unselected patients with lorlatinib-resistant NSCLC, underscoring the need for more effective and biomarker-informed treatment strategies.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement • ROS1 rearrangement
    |
    Lorbrena (lorlatinib) • Mektovi (binimetinib) • batoprotafib (TNO155)
    22d
    Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=34, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed
    Trial completion
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Ibrance (palbociclib) • Mektovi (binimetinib)
    23d
    Safety and Efficacy of Triple Therapy Containing Encorafenib, Cetuximab, and Binimetinib for BRAF V600E-Mutated Colorectal Cancer: a Systematic Review and Meta-Analysis. (PubMed, J Gastrointest Cancer)
    Triple therapy with encorafenib, cetuximab, and binimetinib offers meaningful improvements in survival and tumor response in BRAF V600E-mutated CRC, although the toxicity remains substantial. Optimizing patient selection and managing adverse events are critical for broader clinical use.
    Clinical • Retrospective data • Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • Braftovi (encorafenib)
    29d
    Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2028 --> Dec 2026
    Trial completion date
    |
    BRAF V600E • BRAF V600
    |
    Opdivo (nivolumab) • Mektovi (binimetinib) • Braftovi (encorafenib)
    1m
    Remission of metastatic duodenal cancer after treatment with BRAF inhibitor (PubMed, Ugeskr Laeger)
    Encorafenib, cetuximab, and binimetinib are targeted therapies developed for metastatic colorectal cancer with a BRAF V600E mutation. The case highlights the potential use of BRAF V600E targeted therapy in BRAF V600E-mutated duodenal cancer and the importance of molecular profiling in rare cancers. Further research is needed on the effect and safety of targeted therapy for small bowel adenocarcinoma.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • Braftovi (encorafenib)
    1m
    EAY191-A6: Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> May 2026 | Trial primary completion date: Jan 2026 --> May 2026
    Trial completion date • Trial primary completion date
    |
    MAPK1 (Mitogen-activated protein kinase 1)
    |
    BRAF V600E • BRAF V600
    |
    Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical
    2ms
    Long lasting response to the combination of Avutometinib and Defactinib after progression on Binimetinib in a patient with recurrent low grade serous ovarian carcinoma - A case report. (PubMed, Gynecol Oncol Rep)
    The oral drug combination was well tolerated with no dose-limiting toxicity or need for dose reduction over the 4 year period. The Avutometinib and Defactinib combination may represent a new standard treatment option for platinum-resistant and AI-resistant/recurrent LGSOC who have failed other MEKi.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    KRAS mutation
    |
    Mektovi (binimetinib) • Avmapki (avutometinib) • Fakzynja (defactinib)
    2ms
    Exploratory Analysis of Biomarkers and Treatment Outcomes From the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma. (PubMed, Clin Cancer Res)
    The greatest benefits of encorafenib plus binimetinib were observed in patients with evidence of high TMB and/or tumor immune infiltration, suggesting potential immune contributions to efficacy, which were not observed with vemurafenib. BRAF V600 detectability in ctDNA appears to have utility as a marker of prognosis and response in this population.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • IFNG (Interferon, gamma)
    |
    PD-L1 expression • BRAF V600E • TMB-H • BRAF V600 • BRAF V600K
    |
    Zelboraf (vemurafenib) • Mektovi (binimetinib) • Braftovi (encorafenib)